155 related articles for article (PubMed ID: 15792683)
1. Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays.
Liestøl S; Wisløff F
Thromb Res; 2005; 115(6):509-17. PubMed ID: 15792683
[TBL] [Abstract][Full Text] [Related]
2. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied.
Moore GW; Savidge GF
Thromb Res; 2006; 118(4):523-8. PubMed ID: 16263154
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the low molecular weight heparin dalteparin in cats.
Mischke R; Schmitt J; Wolken S; Böhm C; Wolf P; Kietzmann M
Vet J; 2012 Jun; 192(3):299-303. PubMed ID: 21978598
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of sensitivity and specificity of confirmatory assays for lupus anticoagulant (LA) detection].
Imoto K; Yasumuro Y; Taki M; Suzuki Y; Akatu S; Tajima C; Ichikawa Y
Rinsho Byori; 1996 Aug; 44(8):797-801. PubMed ID: 8816068
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers.
Lawrie AS; Mackie IJ; Purdy G; Machin SJ
Thromb Haemost; 1999 May; 81(5):758-62. PubMed ID: 10365750
[TBL] [Abstract][Full Text] [Related]
7. Further evidence of false negative screening for lupus anticoagulants.
Moore GW; Henley A; Greenwood CK; Rangarajan S
Thromb Res; 2008; 121(4):477-84. PubMed ID: 17602725
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
Millet J; Jouault SC; Mauray S; Theveniaux J; Sternberg C; Boisson Vidal C; Fischer AM
Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467
[TBL] [Abstract][Full Text] [Related]
9. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
10. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Ragland BD; Reed CE; Eiland BM; Tichenor PH; Hudson CL; Fritsma GA; Adler BK; Marques MB
Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
[TBL] [Abstract][Full Text] [Related]
11. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Cavusoglu E; Lakhani M; Marmur JD
J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
[TBL] [Abstract][Full Text] [Related]
12. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
13. Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test.
Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N; Suzuki T; Aoki T
Thromb Res; 2014 Aug; 134(2):503-9. PubMed ID: 24935674
[TBL] [Abstract][Full Text] [Related]
14. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
Robert A
Thromb Haemost; 1994 Feb; 71(2):220-4. PubMed ID: 8191402
[TBL] [Abstract][Full Text] [Related]
15. Conceptions and misconceptions in testing for lupus anticoagulants.
Exner T
J Autoimmun; 2000 Sep; 15(2):179-83. PubMed ID: 10968906
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
18. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing.
Näsström B; Stegmayr B; Gupta J; Olivecrona G; Olivecrona T
Nephrol Dial Transplant; 2005 Jun; 20(6):1172-9. PubMed ID: 15797889
[TBL] [Abstract][Full Text] [Related]
19. The Activated Seven Lupus Anticoagulant (ASLA) test has comparable sensitivity to classical assays for screening of lupus anticoagulant.
Marinuzzo M; Adamczuk Y; Varela ML; Pombo G; Forastiero R
Thromb Haemost; 2005 May; 93(5):1007-9. PubMed ID: 15900652
[No Abstract] [Full Text] [Related]
20. [Sensitivity of new reagents for laboratory monitoring of low molecular weight heparin: an in vitro study].
Shi XB; Wang JQ; Wang JY; Hou XX; Ma ZM
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(22):1566-8. PubMed ID: 21914372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
